TECH · News · 20260807N

Acquisition / Partnership / Divestiture

BIO-TECHNE Corp · 2026-08-07 · Importance 65 · Surprise 60

Bio-Techne recently agreed to be acquired by Merck KGaA. The proposed transaction is expected to strengthen Merck’s position in high-growth life science markets. The deal was cited alongside Merck’s increased 2026 outlook and stronger second-quarter results, but the reported coverage did not disclose a transaction value or closing timeframe.

Key facts

• Amundi reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 67.2% during the first quarter, selling 148,342 shares and retaining 72,315 shares valued at approximately $3.8 million. source
• Merck raised its full-year guidance for 2026 after reporting stronger-than-expected second-quarter results. source
• Merck's proposed acquisition of Bio-Techne Corporation is expected to further bolster its leadership in high-growth life science markets. source
• Institutional ownership of Bio-Techne remained high at 98.95%. source